Trevi Therapeutics News

Trevi Therapeutics to Present Phase 2 Results of Haduvio for Chronic Cough at ATS 2024 Conference

Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in idiopathic

BenzingaApr 9 19:32

Needham: Reiterates the Trevi Therapeutics (TRVI.US) rating, adjusted from buy to buy, with a target price of $8.00.

Needham: Reiterates the Trevi Therapeutics (TRVI.US) rating, adjusted from buy to buy, with a target price of $8.00.

Zhitong FinanceApr 9 18:10

Trevi Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/09/2024 155.18% Needham → $8 Reiterates Buy → Buy 03/21/2024 187.08% Oppenheimer $9 → $9 Maintains Outp

BenzingaApr 9 18:04

CALM,PLAY and VNDA Are Among After Hour Movers

Seeking AlphaApr 3 04:43

Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Oculis Holding (OCS) and Quanterix (QTRX)

TipRanksMar 25 09:30

Buy Rating for Trevi Therapeutics Anchored on Haduvio's Clinical Promise and Market Potential

TipRanksMar 22 20:05

Trevi Therapeutics Price Target Maintained With a $9.00/Share by Oppenheimer

Trevi Therapeutics Price Target Maintained With a $9.00/Share by Oppenheimer

Dow JonesMar 21 21:02

Analysts' Opinions Are Mixed on These Healthcare Stocks: Vor Biopharma (VOR), Roche Holding AG (OtherRHHVF) and Trevi Therapeutics (TRVI)

TipRanksMar 21 19:50

Trevi Therapeutics (TRVI) Receives a Buy From Stifel Nicolaus

TipRanksMar 21 19:27

Needham Reiterates Buy on Trevi Therapeutics, Maintains $8 Price Target

Needham analyst Serge Belanger reiterates Trevi Therapeutics with a Buy and maintains $8 price target.

Analyst UpgradesMar 21 18:53

Analysts' Top Healthcare Picks: Trevi Therapeutics (TRVI), Walgreens Boots Alliance (WBA)

TipRanksMar 21 18:10

Q4 2023 Trevi Therapeutics Inc Earnings Call

Yahoo FinanceMar 21 18:03

Earnings Call Summary | Trevi Therapeutics(TRVI.US) Q4 2023 Earnings Conference

The following is a summary of the Trevi Therapeutics, Inc. (TRVI) Q4 2023 Earnings Call Transcript:Financial Performance:No financial performance details provided for this period.Business Progress:Tre

Futu NewsMar 21 06:24 · Conference Call

Trevi Therapeutics Inc (TRVI) Announces Year-End Financials and Progress in Clinical Trials

Yahoo FinanceMar 21 05:33

ARAY, AXTI and LZ Are Among After Hour Movers

Seeking AlphaMar 21 04:52

Trevi Therapeutics: Q4 Earnings Insights

Trevi Therapeutics (NASDAQ:TRVI) reported its Q4 earnings results on Wednesday, March 20, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsTrevi Therapeutics beat est

BenzingaMar 21 04:20

Trevi Therapeutics Q4 2023 GAAP EPS $(0.08) Beats $(0.09) Estimate

Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent.

BenzingaMar 21 04:19

Press Release: Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates

Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates PR Newswire NEW HAVEN, Conn., March 20, 2024 Reaffirms guidance for the Phase 2a RIVER tr

Dow JonesMar 21 04:05

Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates

Reaffirms guidance for the Phase 2a RIVER trial of Haduvio in RCC patients with topline data expected in the second half of 2024 Enrollment progressing in the Phase 2b CORAL dose-ranging trial of Had

Trevi TherapeuticsMar 20 12:00

Earnings Outlook For Trevi Therapeutics

Trevi Therapeutics (NASDAQ:TRVI) is set to give its latest quarterly earnings report on Wednesday, 2024-03-20. Here's what investors need to know before the announcement.Analysts estimate that Trevi T

BenzingaMar 20 00:01